FDA committee meets to consider Exact Sciences cancer test

An FDA committee is meeting today to discuss an application from Madison-based Exact Sciences to market its colorectal cancer screening test.

The Molecular and Clinical Genetics Panel has an all-day meeting scheduled in Maryland, with a vote set for 3:30 p.m. Central time.

The NASDAQ halted trading of the company’s stock this morning in advance of the panel, as it often does.

See the meeting agenda and related documents